Diagnostic composition for neurotransmission disorder diseases by utilizing agrin

A technology for neurotransmission disorders and diagnostic compositions, which can be used in disease diagnosis, biological testing, and biomaterial analysis. It can solve the problems of non-detection and achieve the effect of filling vacancies, good results, and broad market prospects.

Inactive Publication Date: 2014-06-18
NANCHANG UNIV
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, 20% of patients have undete...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnostic composition for neurotransmission disorder diseases by utilizing agrin
  • Diagnostic composition for neurotransmission disorder diseases by utilizing agrin
  • Diagnostic composition for neurotransmission disorder diseases by utilizing agrin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1 LRP4 autoantibodies exist in the blood of patients with myasthenia gravis, which can induce myasthenia gravis

[0025] Myasthenia gravis, an autoimmune disease, is a common neurosynaptic disease, affecting about 10-20 per 100,000 people. About 80% of patients have antibodies in their body that can bind to muscle acetylcholine receptors. These antibodies reduce the number of acetylcholine receptors or disable them, resulting in muscle weakness in neuromuscular transmission. Although most cases of myasthenia gravis are caused by autoantibodies that bind to acetylcholine receptors, about 20% of patients have undetectable antibodies to acetylcholine receptors. In 2001, about 4-50% of patients with negative acetylcholine receptor antibody could detect MuSK antibody. Immunization of rabbits with the extracellular region of MuSK can lead to myasthenia gravis and decrease in the number of acetylcholine receptors. Although a series of experiments demonstrated that an...

Embodiment 2

[0043] Example 2 Autoantibodies from patients with myasthenia gravis bind to agrin

[0044] The sera of some patients with myasthenia gravis were negative for acetylcholine receptor antibody / MuSK antibody / LRP4 antibody, which may indicate the existence of new unknown autoantibodies. The present invention demonstrates the presence of antibodies to the agrin-containing protein in the sera of these patients. This example proves that among 93 patients with myasthenia gravis, 7 sera were positive for agglutinin antibodies (about 7-8%), while no positive for agglutinin antibodies was found in healthy people or other patient controls. This invention demonstrates that aggrin antibodies are a novel pathogen in patients with myasthenia gravis.

[0045] Experiments have proved that aggrin antibody serum can recognize aggrin, and can inhibit the phosphorylation of MuSK protein induced by aggrin, and can inhibit the aggregation of aggrin on acetylcholine receptors. This invention proves ...

Embodiment 3

[0054] Example 3 Preparation method and detection process of LRP4 autoantibody detection kit

[0055] Myasthenia gravis, an autoimmune disease, is a common neurosynaptic disease, affecting about 10-20 per 100,000 people. About 80% of patients have antibodies in their body that can bind to muscle acetylcholine receptors. These antibodies reduce the number of acetylcholine receptors or disable them, resulting in muscle weakness in neuromuscular transmission. In patients with negative acetylcholine receptor antibodies, MuSK antibodies can be detected in about 4-50% of patients. Although a series of experiments demonstrated that antibodies to acetylcholine receptors and MuSK caused myasthenia gravis, these antibodies were still undetectable in 10% of patients. This example describes the preparation method of the LRP4 autoantibody enzyme-linked immunosorbent assay (ELISA) detection kit, and the process of using the kit to detect LRP4 antibody in patients with double-negative acety...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of biology, and discloses a diagnostic composition for neurotransmission disorder diseases by utilizing agrin. The diagnostic composition comprises agrin or agrin mimic epitope. The composition can be used for diagnosing neurotransmission disorder diseases, and has an excellent effect and wide market prospects.

Description

technical field [0001] The invention belongs to the field of biotechnology and relates to a diagnostic composition. Background technique [0002] Neurotransmission disorders Myasthenia gravis is an autoimmune disease that causes dysfunction of the neuromuscular junction. 70% of patients with myasthenia gravis carry autoantibodies to acetylcholine receptors, and another 10% of patients carry autoantibodies to MuSK. However, 20% of patients had no detectable autoantibodies to acetylcholine receptor or MuSK in serum. Therefore, there is a need for a diagnostic composition for neuromuscular related diseases such as myasthenia gravis. Contents of the invention [0003] The present invention provides a diagnostic composition for neurotransmission disorders. [0004] Specific technical solutions: [0005] A diagnostic composition targeting neurotransmission disorders using aggregins, comprising human low-density lipoprotein receptor-associated protein 4 aggregins or aggregin ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68G01N33/531
CPCG01N33/564G01N33/6896G01N2800/28
Inventor 梅林熊文诚张斌沈承勇罗时文
Owner NANCHANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap